EP2247944A1 — Gamma probe detection of amyloid plaque using radiolabeled a-beta binding compounds
Assigned to Avid Radiopharmaceuticals Inc · Expires 2010-11-10 · 16y expired
What this patent protects
The present invention relates to a method of detecting β-amyloid peptide aggregates in the brain of an individual and kits thereto. The method includes administering to an individual an effective amount of an Aβ-binding radiopharmaceutical, waiting a period of time, measuring a g…
USPTO Abstract
The present invention relates to a method of detecting β-amyloid peptide aggregates in the brain of an individual and kits thereto. The method includes administering to an individual an effective amount of an Aβ-binding radiopharmaceutical, waiting a period of time, measuring a gamma radiation count over an external area of the head corresponding to the cortex of the individual using a radiation detection device, and comparing the gamma radiation count with a control gamma radiation count.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.